Article Information
History
- May 10, 2024.
Article Versions
- Version 1 (April 19, 2024 - 17:13).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Howard H. Feldman1,2,3,*,¶,
- José A. Luchsinger4,¶,
- Gabriel C. Léger1,2,
- Curtis Taylor1,2,
- Diane M. Jacobs1,2,3,
- David P. Salmon1,2,3,
- Steven D. Edland1,2,3,
- Karen Messer1,2,
- Carolyn Revta1,2,
- Sarah A. Flowers5,
- Kerry S. Jones6,
- Albert Koulman6,
- Kevin E. Yarasheski7,
- Philip B. Verghese7,
- Venky Venkatesh7,
- Henrik Zetterberg8,9,10,11,12,13,
- January Durant1,2,
- Jody-Lynn Lupo1,2,
- Gary E. Gibson14,¶,
- the ADCS BenfoTeam Study Group^
- 1Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
- 2Alzheimer’s Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
- 3Shiley-Marcos Alzheimer’s Disease Research Center, La Jolla, California, United States of America
- 4Columbia University Irving Medical Center, New York, New York, United States of America
- 5University of Virginia, Charlottesville, Virginia, United States of America
- 6Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
- 7C2N Diagnostics, St. Louis, Missouri, United States of America
- 8Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- 9Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- 10Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
- 11UK Dementia Research Institute at UCL, London, UK
- 12Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
- 13Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA
- 14Burke Neurological Institute, Weill Cornell Medicine, White Plains, New York, United States of America
- ↵*Corresponding author: E-mail: howardfeldman{at}health.ucsd.edu (HF)
↵¶ These authors contributed equally to this work.
Posted May 10, 2024.
Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)
